To determine whether intracerebrally localized iodothyronines produce thyroid hormone-related functional effects, heart rate responses were compared in conscious hypothyroid rats given triiodothyronine (T3) by either the intrathecal or the intravenous route. A significant increase in heart rate occurred within 18 h after 1.5 amol T3/100 g body wt was delivered intrathecally through a cannula previously placed in the lateral cerebral ventricle. Injection of the same T3 dose intravenously through an indwelling jugular catheter or injection of vehicle only by either route produced no significant increase in heart rate during the 48-h postipiection period of observation. These differences were observed even though integrated serum T3 concentrations were significantly lower after intrathecal than after intravenous T3 injection. The results indicate that thyroid hormone effects on heart rate are exerted within the brain as well as within the heart.
Introduction
Recent observations have demonstrated that brain iodothyronines are under strong homeostatic control (1) , cross the bloodbrain barrier through a high-affinity transport mechanism (2) , are actively metabolized (3, 4) and processed in discrete neural pathways (5) , are concentrated in synaptosomes (3, 6) , and bind with high affinity to a limited number ofsites in nerve cell nuclei (7) and synaptosomes (8) . Thus far, however, only indirect evidence suggests that intracerebrally localized thyroid hormones produce changes in neural structure (9) or function (10) .
To test for a causal relationship between brain iodothyronines and nervous system activity, we measured the effect of a single injection oftriiodothyronine (T3)' or vehicle given intrathecally on an adrenergically responsive process, heart rate, in conscious hypothyroid rats. Although the amount of T3 given (1.5 nmol/ 100 g body wt) was considerably less than that previously reported to cause an increase in heart rate when given systemically in rats given thyroxine (T4) or reverse triiodothyronine (rT3) intrathecally. Moreover, when heart rate response to intrathecal T3 was compared with the response after intravenous T3 or vehicle given by either route, a significant increase in heart rate was noted only in animals given T3 intrathecally.
Methods
Surgically thyroidectomized rats received from Zivic-Miller Laboratories (Allison Park, PA) were given free access to Purina chow (Ralston Purina Co., St. Louis, MO) and 0.5% CaC12 as drinking water. All rats showed the expected plateau in body weight gain; the duration of hypothyroidism was 3-6 wk in the first and second experiments and 2-4 wk in the third and fourth experiments. Rats used in any one experiment were ofsimilar age, were thyroidectomized on the same day, and were housed in a laboratory space dedicated exclusively to the experiment. All animal care was administered and all treatments were carried out by a single investigator.
Experiment no. 1. Rats were paired by body weight (range, 200-250 g) and were handled as pairs throughout. Rats were anaesthesized with intraperitoneal nembutal (40 mg/kg) and atropine (0.1 mg/kg), and a 23-gauge cannula was lowered through a burr hole in the left lateral cerebral ventricle (coordinates: 0.6 mm posterior to bregma, 1.5 mm lateral to saggital sinus, 3.0 mm below dura), using stereotactic guidance (12) . A small incision was made over the precordial area and a fine teflon-coated Medwire (50 ,M; Medwire Corp., Mt. Vernon, NY), bared at its end, was sutured to the subcutaneous fat and passed subcutaneously until exteriorized at the nape of the neck; a second length of Medwire was placed subcutaneously over the cranium to act as a reference electrode. The free ends ofboth wires were placed in a male microconnector strip (2 X 5 X 10 mm) and secured along with the intraventricular cannula to the skull with self-tapping screws and Craniofacial Cement (Plastic Products, Roanoke, VA). 2 d later, when the rats were fully recovered, the monitoring leads were connected via a female microconnector strip and flexible protected cable to a preamplifier and recorder wired to an electronic timer, this was arranged as to allow the animals to move about freely in their cages. Heart rate was recorded simultaneously every 30 min in each member of the pair. After 18 h of recording to allow adaptation to the equipment and obtain base-line values, one rat of each pair was given 1.5 nmol T3/100 g body wt in 4 Ml of0.2 N NaOH, which was delivered through the cannula over 120 s, while the other rat of the pair received 4 eraged to obtain a mean heart rate for each 2-h postinjection period; corresponding values obtained from vehicle-treated (n = 5) or T3-treated (n = 5) rats were then averaged to obtain an overall mean 2-h value±SD. Experiment no. 2. To control for the possibility ofa nonspecific effect ofintrathecally administered iodothyronine, rats prepared and monitored as described in the first experiment were given 1.5 nmol/100 g body wt of T4 (n = 4), rT3 (n = 5), or NaOH (n = 4) intrathecally.
Experiment no. 3. To compare the heart rate-modifying effect of intravenous T3 with that of intracerebral T3, silicone jugular venous catheters (0.037 cm o.d., Silastic; Dow Coming Corp., Midland, MI) were implanted in hypothyroid rats (150-200 g body wt) otherwise prepared and monitored as described in the first experiment. Pairs of rats were given 1.5 nmol T3/100 g body wt or NaOH by intravenous or intrathecal injection (see experiment 4 for intravenous injection volumes) and were observed simultaneously (n = 6 in each category).
Experiment no. 4. To compare changes in serum T3 concentrations after intrathecal and intravenous administration, matched pairs of hypothyroid rats averaging 260 g body wt had the required cannulas implanted under anaesthesia; 2 d later, seven rats received 3.9 nmol T3 in 4.0 Ml of 2 N NaOH intrathecally and four rats received the same amount of intravenous T3 given in 130 Ml of 6 X 10-4 NaOH through the indwelling silicone tubing and followed by I ml of saline. Experiments with '25I-T3 revealed no adsorption of T3 to the tubing. 1 ml of blood for T3 measurement was withdrawn and replaced by an equal volume ofsaline immediately before T3 administration, and again at 5 min (preceded by 0.02 ml blood withdrawn and discarded at that interval only) and the other time intervals shown on the abscissa in Fig. 4 . Serum was separated in a refrigerated centrifuge and T3 was measured by radioimmunoassay (13) . All determinations were made in a single assay; the intraassay coefficient of variation was -5%.
Data analysis. To avoid overestimation of significant differences in analyzing sequential heart rate changes, the method ofmultivariate analysis of variance for repeated measures was chosen. This method allows correlations between time points without assuming independence between points or equal correlations over time (14) . It compares treatment groups in terms of both the overall level of heart rate (constant term) and the shape of the time trends. The shape of the time trends are modeled on a third degree orthogonal polynomial, thus allowing comparisons of the linear rate of change (x term) and the pattern of response (X2 and X3 terms) between groups. All data are expressed as the mean±SD.
Results
Effect of intrathecal T3 (Fig. 1) . All rats received either T3 or vehicle intrathecally. The heart rate did not change in response to vehicle (base-line heart rate: 332±29 beats per minute (bpm) after intrathecal NaOH: 331±21 bpm). In T3-treated rats, the heart rate increased significantly from 326±24 bpm before to 343±25 bpm after intrathecal administration (P < 0.02). Comparison of results in T3-treated vs. vehicle-treated animals revealed significant differences in both the overall heart rate level (F = 8.5, degrees of freedom (df) = 1, 8; P < 0.02) and the rate of heart rate change over time (F = 5.0, df = 1, 8; P < 0.05). The results indicate that T3 enhanced heart rate overall and that this occurred in a linearly increasing fashion. This is apart from the diurnal pattern of heart rate response which is apparent and similar in both groups.
Effect ofother iodothyronines (Fig. 2) . To exclude the possibility that the results after intrathecal T3 were due to nonspecific heart rate-stimulating effects of intrathecally administered iodothyronine, a three-way comparison of heart rates was carried out after administration of 1.5 nmol/100 g body wt of either T4, rT3, or NaOH. The heart rate did not change significantly in any group and pre-and postinjection values were not significantly different among groups (pre-and postinjection values, respectively: T4, 329±27 and 339±22 bpm; rT3, 308±21 and 301±30 bpm; NaOH, 322±29 and 327±16 bpm).
Effect of intravenous T3 (Fig. 3) . Additional experiments were Figure 1 . Fractional heart rate changes after intrathecal administration of T3 or vehicle. Hypothyroid rats were prepared and monitored as described in Methods. Mean heart rates for each 2-h postinjection period is expressed as a fraction of the mean base-line heart rate±SD. The overall difference between vehicle-treated and T3-treated rats was significant (P < 0.02); t test at each time interval showed significant differences as indicated by *(P < 0.05) or t(P < 0.02); n = 5.
conducted to confirm the intrathecal T3 effect and to determine the heart rate response in intravenous T3-treated animals when handled and evaluated by the methods used in these investigations. A four-way comparison of heart rate was carried out after administration of T3 or vehicle by the intrathecal or intravenous route. A diurnal variation in heart rate response was not observed in any offour groups ofrats studied in this experiment, although it was observed in the groups studied in the first and second experiments (see Figs. 1 and 2 ). The reason for this difference is unclear.
Base-line and posttreatment heart rates, respectively, were: 372±26 and 369±34 bpm, intrathecal NaOH; 370±34 and 394±27 bpm, intrathecal T3; 382±34 and 358±43 bpm, intravenous NaOH; 380±24 and 379±25 bpm, intravenous T3. Multivariate analysis of variance for repeated measures showed an overall increase over base-line heart rates only in rats given 110 Figure 2 . Mean fractional heart rate changes+SD after intrathecal administration of 1.5 nmol T4 or rT3/100 g body wt or vehicle to rats prepared and monitored as described in experiment 1. No significant heart rate change over base line was noted in any group; overall differences in postinjection heart rates among rats given T4, rT3, or NaOH were not significant. * .. o * ., NaOH; -* -, rT3; A, T4. intrathecal T3; these increases were established by 18 h after injection and were significant whether compared with rates after intrathecal NaOH (F = 8.3, df = 4, 10; P < 0.01) or intravenous T3 (F = 5.3, df = 4, 10; P < 0.04). No significant heart rate change was found in the rats given NaOH and no significant differences were noted between rats receiving NaOH by the intravenous vs. the intrathecal route (P < 0.24). Though overall heart rate responses of rats given intravenous T3 were not significantly different from those given intravenous NaOH (P < 0.13), the possibility that a delayed effect of intravenous T3 would have appeared if the experiment had been prolonged beyond 48 h was suggested by a linear trend toward increased heart rate which approached significance (P < 0.08). Serum T3 levels after intravenous and intrathecal T3 administration (Fig. 4) . To determine the rapidity and extent that intrathecally administered T3 appears in the bloodstream, we compared serum T3 levels (radioimmunoassay) in a separate group of matched hypothyroid rats given T3 by the intravenous or intrathecal route. Time-integrated serum T3 values were significantly higher in the intravenous-treated animals (P < 0.01). Therefore, the heart and other peripheral tissues were exposed to significantly higher serum concentrations of T3 after intravenous than after intrathecal T3 administration.
Discussion
Thyroid hormones pass from blood to brain by a carrier-mediated mechanism with affinity for T3 which is reported to exceed that of any known hormone transport system operating across Figure 4 . Serum T3 concentrations following intravenous or intrathecal T3 administration. Base-line T3 values of the two groups were in the hypothyroid range and were not significantly different from each other. Differences between the groups were significant at 5, 50, and 150 min but not thereafter; at 24 and 48 h, serum T3 levels had returned to base line in the intravenous T3-injected group but were still significantly above base line in the intrathecally T3-injected animals. Integrated T3 values were significantly higher by 40% in rats receiving the hormone intravenously (P < 0.01) as compared with rats treated by the intrathecal route.
the blood-brain barrier (2) . However, the capacity ofthis system is small, and as a result, T3 in the systemic circulation equilibrates very slowly with brain, with a half-time between 3 and 6 h (3). Therefore, centrally mediated effects of T3 reaching the brain through the systemic circulation are likely to be delayed as compared with T3 effects in peripheral tissues. We have observed that T3 administration by the intrathecal route results in a faster rate of uptake and a greater concentration of hormone within the brain as compared with results after intravenous administration (data not shown). While intrathecal injection does not guarantee more efficient or rapid delivery to any particular brain region, circumventing the blood-brain barrier by using the intrathecal route has proven to be useful in promoting brain uptake of many compounds (15) .
The T3 dose used in these experiments (1,000 ng/100 g) is higher than considered physiologic (serum T3 production rate in the rat is -200-250 ng/100 g per d). However, functional responses of hypothyroid subjects to a physiologic thyroid hormone dose usually follows repeated administration of that amount. When the response to a single dose of T3 is being evaluated, it is usual to give a dose at an order of magnitude greater than we gave in these experiments (for examples, see references 1 1, 16, and 17) . Evidence that we chose an appropriate dose for these investigations is indicated by the responses themselves. A sensitive indicator of T3 effects, heart rate, did not change significantly when 1.5 nM T3 was given intravenously, whereas a small but significant heart rate change was caused by intrathecal injection of the same amount. It would have been interesting to observe the response to even larger amounts of T3, but the dose was limited by the solubility of the hormones and the requirement to inject no more than a 4-ul volume into the lateral cerebral ventricle.
Two previous reports have shown that a significant increase in core temperature occurs following intrathecal T4 administra-tion (18, 19) . While the evidence is compatible with a central nervous system mechanism of T4 action, the experiments were not controlled so as to examine this point specifically. We chose to study effects of central nervous system iodothyronines on heart rate because this function is (a) dependent not only on peripheral mechanisms but also on mechanisms integrated and controlled in the brain (20) ; (b) markedly susceptible to changes in thyroid hormone availability (21) ; (c) stimulated by thyroid hormones at least in part through a nervous system-related mechanism (22) ; and (d) susceptible to quantitative measurements. Under the conditions of these experiments, no heart rate change was observed after intrathecal T4 or rT3, indicating that the response measured was specific to T3. We ascribe the greater (or earlier) heart rate change observed after intrathecal as compared with intravenous T3 to its earlier uptake and higher concentration in T3-responsive centers in brain.
While the data reported here point to a T3-responsive central nervous system mechanism in heart rate regulation, the results in no way detract from the heart rate-stimulating effects of T3 exerted within the neural or myocardial components of the heart itself. Rather, bidirectional passage of iodothyronines across the blood-brain barrier (23) would make it likely that both central and peripheral iodothyronine-dependent processes are involved in regulating cardiovascular dynamics. Though the cellular mechanism is still unknown, the information provided by this study adds to existing biochemical and autoradiographic evidence (3, 5, 6) supporting a neuroregulatory role for T3 or its metabolites within the central nervous system.
